

Remarks

This preliminary amendment is being filed in conjunction with the entry into the U.S. National Phase of PCT application PCT/US2004/014263, which included claim 1-57.

By way of this preliminary amendment, claims 34, 38-42 and 45-48 are canceled without prejudice, and claims 1, 4-9, 14-22, 25, 26, 28, 31-33, 35-37, 43, 44, 49-51, 56 and 57 are amended.

Upon entry of this preliminary amendment, claims 1-33, 35-37, 43, 44 and 49-57 will be pending.

The specification has been amended to incorporate a paragraph regarding cross-referencing the chain of priority.

The subject matter of claims 1 and 45 have been combined as a single claim presented in Markush format as amended claim 1.

Claims 4-9 have been amended to eliminate multiple dependencies. As amended, each of claims 4-9 refer to the step of administering an ATP citrate lyase inhibitor and are dependent on claim 1.

Claims 14 and 15 have been amended to eliminate multiple dependencies. As amended, each of claims 14 and 15 are dependent on claim 10.

The subject matter of claims 16 and 34 have been combined as a single claim presented in Markush format as amended claim 16.

Claims 17 and 18 have been amended to specifically refer to the step of administering an ATP citrate lyase inhibitor.

Claims 19-22 have been amended to eliminate multiple dependencies. As amended, each of claims 19-22 refer to the step of administering an ATP citrate lyase inhibitor and are dependent on claim 16.

Claims 25 and 26 have been amended to eliminate multiple dependencies. As amended, each of claims 25 and 26 are dependent on claim 16.

The subject matter of claims 28 and 42 have been combined as a single claim presented in Markush format as amended claim 28.

Claims 29 and 30 have been amended to specifically refer to the step of delivering an ATP citrate lyase inhibitor to the cell.

Claim 31 has been amended to eliminate its multiple dependency. As amended, claim 31 is dependent on claim 28.

Claims 32 and 33 have been amended to eliminate multiple dependencies. As amended, each of claims 32 and 33 refer to the step of delivering an ATP citrate lyase inhibitor to the cell and are dependent on claim 28.

Claims 34 and 38-41 have been canceled in view of the amendment of claim 16.

Claim 35 has been amended to specifically refer to the step of administering a tricarboxylate transporter inhibitor and to be dependent on claim 16.

Claims 36 and 37 have been amended to eliminate multiple dependencies. As amended, each of claims 36 and 37 refer to the step of administering a tricarboxylate transporter inhibitor and are dependent on claim 16.

Claim 42 has been canceled in view of the amendment of claim 28.

Claim 43 has been amended to specifically refer to the step of administering a tricarboxylate transporter inhibitor and to be dependent on claim 28.

Claim 44 has been amended to eliminate its multiple dependency. As amended, claim 44 refers to the step of administering a tricarboxylate transporter inhibitor and is dependent on claim 28.

Claims 45-48 have been canceled in view of the amendment of claim 1.

Claim 49 has been amended to eliminate its multiple dependency. As amended, claim 44 refers to the step of administering a tricarboxylate transporter inhibitor and is dependent on claim 1.

Claims 50 and 51 have been amended to eliminate multiple dependencies. As amended, claims 50 and 51 are dependent on claim 1.


Claims 56 and 57 have been amended to eliminate multiple dependencies. As amended, claims 56 and 57 are dependent on claim 54.

Support for the amendments is found throughout the specification and claims as originally filed. No new matter has been added.

Claims 1-33, 35-37, 43, 44 and 49-57 are in condition for allowance. An early issuance of a Notice of Allowance is earnestly solicited.

Respectfully Submitted

COZEN O'CONNOR

By: 

Mark DeLuca (Reg. No. 33,229)
Cozen O'Connor
1900 Market Street
Philadelphia, PA 19103
(215) 665-5592

Dated: November 9, 2005